Joined-Up EU Approach Is Key To Continuing COVID-19 Fight
Multi-Stakeholder Approach Must Be Maintained, Medicines For Europe Insists
At a Medicines for Europe webinar on learning lessons from the COVID-19 pandemic, a clear consensus emerged that a continued co-ordination between industry, regulators and the European Commission was key to both effectively address the current crisis and ensure a greater level of preparedness for similar challenges in future.
You may also be interested in...
European procurement models that focus solely on the lowest-cost generics are jeopardizing efforts to strengthen the supply chain and secure investments in local manufacturing, says Christoph Stoller, president of Medicines for Europe.
A globally co-ordinated approach to sourcing that rewards non-pricing criteria is imperative to bolster the security of the off-patent industry’s supply chain in the wake of the coronavirus pandemic, James Burt tells Generics Bulletin in the second part of our exclusive interview.
A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.